MSM Methylsulfonylmethane
Description: <b>MSM (Methylsulfonylmethane)</b> is a naturally occurring organosulfur compound often used as a dietary supplement for its anti-inflammatory and antioxidant effects. While most well-known for joint health.<br>
-MSM is actually a metabolite of DMSO (dimethyl sulfoxide)
<pre>
-Generally Recognized as Safe Possible Interactions: aspirin, warfarin, NSAIDS<br>
-Supplement dosage: 500mg 2-3times/day<br>
-Anti-inflammatory: ↓NF-κB, ↓COX-2 and iNOS
-↓STAT3
-↓Cyclin D1 and CDK4, halting cell cycle progression.
-↓MMP-2, MMP-9, VEGF limiting invasion.
</pre>
<p><b>Methylsulfonylmethane (MSM)</b> — a small, naturally occurring organosulfur compound, also called dimethyl sulfone, that is formed in sulfur metabolism and is also a major oxidation product/metabolite of dimethyl sulfoxide (DMSO). It is classified primarily as a dietary supplement/nutraceutical rather than an approved anticancer drug. Standard abbreviations are MSM and DMSO₂. MSM occurs at low levels in foods and biological fluids and is widely used orally for musculoskeletal and inflammatory conditions. Its most reproducible biology is anti-inflammatory and redox-modulating, whereas anticancer effects remain predominantly preclinical and frequently require very high concentrations.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Suppression of STAT3/STAT5b signaling and associated oncogenic transcription, including IGF-1R, HER2 and VEGF pathways.</li>
<li>Suppression of hypoxia-driven HIF-1α signaling, with downstream reduction of glycolytic and metastatic programs including GLUT1, LDHA, PKM2 and VEGF.</li>
<li>Induction of cancer-cell growth arrest and apoptosis, including caspase activation and PARP cleavage in susceptible models.</li>
<li>Suppression of NF-κB-driven inflammatory signaling and inflammatory mediators including COX-2, iNOS, TNF-α, IL-1β and IL-6.</li>
<li>Suppression of NLRP3 inflammasome activation and mitochondrial ROS-dependent inflammatory signaling.</li>
<li>Reduction of migration, invasion and angiogenic/metastatic signaling, particularly through STAT/HIF-1α/VEGF-related pathways.</li>
<li>Antioxidant/redox-buffering activity in normal or inflammatory tissues, generally reducing excessive ROS rather than acting as a cancer-selective pro-oxidant.</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> MSM is orally absorbed and distributes widely into tissues, including the central nervous system. Human serum concentrations increase during repeated oral supplementation, and available data suggest a systemic half-life greater than approximately 12 hours. Common studied oral doses are approximately 1.5–6 g/day. Oral absorption is therefore not the major translational limitation; the main limitation for cancer applications is the very large exposure gap between supplement-level systemic concentrations and the concentrations used in many anticancer experiments.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> This is a major limitation. Many direct anticancer studies use approximately 100–500 mM MSM; breast-cancer studies commonly used approximately 300 mM and liver-cancer experiments up to 500 mM. Gastrointestinal cancer IC50 values of approximately 22–28 mg/mL correspond to roughly 230–300 mM. These concentrations are orders of magnitude above the low-micromolar endogenous/systemic range and are unlikely to be reproduced by conventional oral supplementation. Consequently, direct cytotoxic anticancer mechanisms should not be assumed to occur at typical human oral doses.</p>
<p><b>Clinical evidence status:</b> Human evidence exists mainly for osteoarthritis, pain, exercise/inflammation and cosmetic/skin outcomes, including small randomized controlled trials using approximately 3–6 g/day. Cancer evidence is preclinical, consisting of cell culture and animal/xenograft studies; convincing human anticancer efficacy has not been demonstrated. MSM should therefore be categorized as preclinical for cancer rather than as an established oncology adjunct.</p>
<br>
<h3>Methylsulfonylmethane Cancer Mechanisms</h3>
<table border="1" cellpadding="4" cellspacing="0">
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
<tr>
<td>1</td>
<td>STAT3 and STAT5b oncogenic signaling</td>
<td>STAT3 ↓; STAT5b ↓; transcriptional activity ↓</td>
<td>↔ (limited evidence)</td>
<td>R, G</td>
<td>Survival and proliferative signaling ↓</td>
<td>One of the strongest cancer-specific MSM mechanisms. Breast and bladder models show suppression of STAT3/STAT5b and downstream oncogenic transcription, but most experiments use concentrations far above achievable systemic exposure.</td>
</tr>
<tr>
<td>2</td>
<td>IGF-1R and HER2 growth signaling</td>
<td>IGF-1R ↓; HER2 ↓; Brk/PTK6 ↓ (model-dependent)</td>
<td>↔</td>
<td>G</td>
<td>Growth signaling ↓</td>
<td>STAT5b-dependent repression of HER2 has been demonstrated in breast-cancer cells; IGF-1R suppression accompanies STAT pathway inhibition in several tumor models.</td>
</tr>
<tr>
<td>3</td>
<td>Hypoxia HIF-1α and glycolytic program</td>
<td>HIF-1α ↓; GLUT1 ↓; PKM2 ↓; LDHA ↓</td>
<td>↔</td>
<td>R, G</td>
<td>Hypoxic adaptation and glycolysis ↓</td>
<td>Under hypoxia, MSM has been reported to suppress HIF-1α and several downstream metabolic adaptations associated with aggressive metastatic phenotypes.</td>
</tr>
<tr>
<td>4</td>
<td>VEGF angiogenic signaling</td>
<td>VEGF ↓; VEGFR2 ↓ (model-dependent)</td>
<td>↔</td>
<td>G</td>
<td>Angiogenic signaling ↓</td>
<td>Closely linked to STAT3 and HIF-1α suppression. Reduced VEGF expression has been demonstrated in breast and bladder tumor models.</td>
</tr>
<tr>
<td>5</td>
<td>Apoptotic caspase pathway</td>
<td>Apoptosis ↑; caspase-8 ↑; caspase-3 ↑; PARP cleavage ↑; Bcl-2 ↓</td>
<td>↔ (model-dependent)</td>
<td>G</td>
<td>Programmed cell death ↑</td>
<td>Documented in breast, hepatic and gastrointestinal cancer models. Direct apoptosis generally occurs at high millimolar concentrations.</td>
</tr>
<tr>
<td>6</td>
<td>Cell-cycle arrest</td>
<td>G2/M arrest ↑; proliferation ↓</td>
<td>↔</td>
<td>G</td>
<td>Cytostasis</td>
<td>Gastrointestinal cancer models show accumulation in G2/M. Cell-cycle effects are secondary to broader signaling disruption and require high concentrations in many studies.</td>
</tr>
<tr>
<td>7</td>
<td>Migration and metastatic phenotype</td>
<td>Migration ↓; invasion ↓; metastatic signaling ↓</td>
<td>↔</td>
<td>G</td>
<td>Metastatic potential ↓</td>
<td>Associated with inhibition of STAT3/STAT5b, VEGF, hypoxia signaling and metabolic reprogramming.</td>
</tr>
<tr>
<td>8</td>
<td>NF-κB inflammatory transcription</td>
<td>NF-κB ↓ (context-dependent)</td>
<td>NF-κB ↓; COX-2 ↓; iNOS ↓; TNF-α ↓; IL-1β ↓; IL-6 ↓</td>
<td>R, G</td>
<td>Inflammatory signaling ↓</td>
<td>This is better established in macrophages, monocytes and inflammatory tissue models than as a direct cancer-cell mechanism. It may nevertheless alter inflammation-associated tumor biology.</td>
</tr>
<tr>
<td>9</td>
<td>NLRP3 inflammasome</td>
<td>NLRP3 ↓ (context-dependent)</td>
<td>NLRP3 ↓; IL-1β ↓; mitochondrial ROS ↓</td>
<td>R, G</td>
<td>Inflammasome activation ↓</td>
<td>MSM selectively suppresses NLRP3 activation in macrophage models. This is principally an anti-inflammatory mechanism rather than demonstrated direct tumor cytotoxicity.</td>
</tr>
<tr>
<td>10</td>
<td>ROS and oxidative stress buffering</td>
<td>ROS ↓ (generally; context-dependent)</td>
<td>ROS ↓; oxidative injury ↓</td>
<td>P, R</td>
<td>Antioxidant activity</td>
<td>MSM should generally be classified as ROS-lowering rather than ROS-generating. This distinguishes it from many anticancer agents whose cytotoxicity depends on oxidative stress.</td>
</tr>
<tr>
<td>11</td>
<td>Radiosensitization or Chemosensitization</td>
<td>Synergy ↑ with selected targeted agents (preclinical); ROS-dependent therapy interaction uncertain</td>
<td>Oxidative and inflammatory injury ↓ (possible)</td>
<td>G</td>
<td>Context-dependent adjunct effect</td>
<td>Synergy has been demonstrated experimentally with the JAK2 inhibitor AG490. There is insufficient evidence to classify MSM broadly as a chemo- or radiosensitizer, and its antioxidant properties create a theoretical concern with strongly ROS-dependent treatments.</td>
</tr>
<tr>
<td>12</td>
<td>Clinical Translation Constraint</td>
<td>Required direct anticancer concentrations often approximately 100–500 mM</td>
<td>Oral doses approximately 1.5–6 g/day generally tolerated short term</td>
<td>G</td>
<td>Exposure mismatch</td>
<td>The large concentration gap between anticancer cell-culture experiments and achievable oral systemic exposure is the principal translational constraint. Human anticancer efficacy has not been established.</td>
</tr>
</table>
<p>P: 0–30 min R: 30 min–3 hr G: >3 hr</p>
<br><br>
<hr>
<br><br>
For Alzheimer's (AD):<br>
Methylsulfonylmethane (MSM) in neurobiology is primarily framed as an anti-inflammatory and redox-buffering molecule, not a direct amyloid-clearing or tau-targeting drug. Evidence is largely preclinical (cell + animal models). Position it as a neuroinflammation and oxidative stress modulator.<br>
<pre>
-Anti-inflammatory: ↓TNF-α, IL-1β, IL-6
-↓ROS, ↑GSH, ↓NO
-may reduce Aβ plaque burden and tau hyperphosphorylation indirectly
-improves memory in rodents
</pre>
<p><b>Methylsulfonylmethane and Alzheimer’s disease:</b> MSM has preliminary neuroprotective evidence but no established human Alzheimer’s disease efficacy. In a rat model of BPA plus γ-radiation-induced AD-like neurotoxicity, MSM reduced oxidative stress and neuroinflammation and ameliorated elevations of Aβ42, phosphorylated tau and acetylcholinesterase while modulating TREM2/DAP12/SYK signaling. Because this is an experimentally induced neurotoxicity model rather than spontaneous human AD, these findings should be classified as preclinical and model-dependent. MSM reaches the human brain, supporting biological plausibility for CNS activity, but therapeutic CNS exposure-response relationships remain poorly defined.</p>
<p><b>Clinical evidence status:</b> Preclinical only for Alzheimer-related outcomes. There are no convincing randomized human trials establishing MSM as an AD treatment.</p>
<br>
<h3>Methylsulfonylmethane Alzheimer-Relevant Mechanisms</h3>
<table border="1" cellpadding="4" cellspacing="0">
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Modulation</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
<tr>
<td>1</td>
<td>Neuroinflammation</td>
<td>TNF-α ↓; IL-1β ↓; inflammatory signaling ↓</td>
<td>R, G</td>
<td>Neuroinflammatory burden ↓</td>
<td>Supported in an AD-like toxin/radiation rat model and consistent with the broader anti-inflammatory pharmacology of MSM.</td>
</tr>
<tr>
<td>2</td>
<td>Oxidative stress</td>
<td>Oxidative stress ↓</td>
<td>P, R</td>
<td>Redox injury ↓</td>
<td>A central protective mechanism across MSM neurotoxicity and inflammatory models.</td>
</tr>
<tr>
<td>3</td>
<td>TREM2 DAP12 SYK signaling</td>
<td>Pathologic activation ↓ toward control</td>
<td>R, G</td>
<td>Microglial signaling normalization</td>
<td>Directly examined in the BPA plus γ-radiation neurodegeneration model.</td>
</tr>
<tr>
<td>4</td>
<td>Amyloid beta pathology</td>
<td>Aβ42 ↓; Aβ deposition ↓</td>
<td>G</td>
<td>Amyloid-associated pathology ↓</td>
<td>Demonstrated in one AD-like rat model; should not be interpreted as proof of direct amyloid-targeting activity in human AD.</td>
</tr>
<tr>
<td>5</td>
<td>Tau phosphorylation</td>
<td>p-tau ↓</td>
<td>G</td>
<td>Tau-associated pathology ↓</td>
<td>Observed in the same toxin/radiation rat model. The responsible kinase/phosphatase mechanism was not established as a primary MSM target.</td>
</tr>
<tr>
<td>6</td>
<td>Acetylcholinesterase</td>
<td>AChE ↓</td>
<td>G</td>
<td>Cholinergic dysfunction ↓</td>
<td>Observed preclinically; no evidence supports equating MSM with clinically established AChE inhibitors.</td>
</tr>
<tr>
<td>7</td>
<td>Clinical Translation Constraint</td>
<td>No established human AD efficacy</td>
<td>G</td>
<td>Evidence limitation</td>
<td>Evidence consists primarily of animal neurotoxicity models despite demonstrated penetration of MSM into the human brain.</td>
</tr>
</table>
<p>P: 0–30 min R: 30 min–3 hr G: >3 hr</p>